Research programme: cognition disorder therapeutics - Cortice Biosciences

Drug Profile

Research programme: cognition disorder therapeutics - Cortice Biosciences

Alternative Names: B1-ADR partial agonist- Cortice Biosciences; CRT 001; Xalmoterol fumarate - Cortice Biosciences

Latest Information Update: 13 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Cortice Biosciences
  • Class Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Down syndrome

Most Recent Events

  • 09 Jul 2015 Cortice Biosciences receives patent allowance for CRT 001 in USA
  • 12 Nov 2014 Pharmacodynamic data from preclinical studies in Alzheimer's disease released by Cortice Biosciences
  • 31 Jul 2014 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top